Aurora's battery of high-throughput cell-based assays will complement Vertex's expertise in chemogenomics and rational drug design. Vertex's decision to acquire Aurora outright is unusual ...

It also aims to use organoids and patient-derived xenografts to take this forward. The proteomic data will be modelled with the Computational Biology and Chemogenomics Team led by Professor Bissan ...